Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 3Prostatic Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia 2Colorectal Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Tinnitus 1Squamous NSCLC 1Solid Tumors 1Sinusitis 1Rib Fractures 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pelvic Pain 1Ovarian Neoplasms 1Ototoxicity 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Metrorrhagia 1Menorrhagia 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leiomyoma 1Kidney Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Extensive Stage Small Cell Lung Carcinoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Squamous NSCLC × 30 days × Clear all
NCT07073183 2026-05-29

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

CureVac

Phase 1 Withdrawn
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡